# Unified Advisory Board Charter

<div align="center">

![Chimera Logo](https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20ADVISORY%20BOARD%20%F0%9F%A6%BE-6236FF?style=for-the-badge&labelColor=1A1A2E)

**Strategic Guidance for Mind-Controlled Exoskeletons**

[![FDA Compliance](https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+)](https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd)
[![CDSCO Compliance](https://img.shields.io/badge/CDSCO-MDR%202017-orange?style=flat-square)](https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/)
[![ISO 13485](https://img.shields.io/badge/ISO%2013485-Compliant-blue?style=flat-square)](https://www.iso.org/standard/59752.html)
[![Make in India](https://img.shields.io/badge/Make%20in%20India-Initiative-orange?style=flat-square)](https://www.makeinindia.com/)
[![BIS](https://img.shields.io/badge/BIS-IS%2023485-green?style=flat-square)](https://www.bis.gov.in/)

**Version 2.0 | April 2025**

</div>

## üìã Document Information

| **Document Information** |                                                |
|--------------------------|------------------------------------------------|
| **Document ID**          | AB-CHARTER-UNIFIED-001                         |
| **Version**              | 2.0.0                                          |
| **Date Created**         | April 18, 2025                                 |
| **Last Updated**         | April 18, 2025                                 |
| **Author**               | Chimera Regulatory Affairs Team                |
| **Reviewers**            | CEO, CTO, Clinical Director, Quality Director, Regulatory Affairs Director |
| **Status**               | Approved                                       |

## üìù Document Revision History

| Version | Date | Author | Description of Changes |
|---------|------|--------|------------------------|
| 1.0.0 | April 10, 2025 | Regulatory Affairs Team | Initial separate charters for FDA and CDSCO |
| 2.0.0 | April 18, 2025 | Regulatory Affairs Team | Unified charter integrating FDA and CDSCO requirements |

## üéØ Purpose and Scope

### 1.1 Purpose

This Unified Advisory Board Charter establishes a comprehensive framework for the formation, operation, and governance of Chimera's Advisory Board. The Advisory Board will provide strategic guidance, expert insights, and regulatory direction for Chimera's brain-computer interface (BCI) controlled exoskeleton system designed to restore mobility for individuals with quadriplegia and other severe mobility impairments.

This unified charter integrates requirements from both US FDA and Indian CDSCO regulatory frameworks while adhering to international standards and industry best practices. By establishing a single, cohesive advisory structure, Chimera aims to eliminate discrepancies and ensure consistent global strategy development.

### 1.2 Scope

This Unified Advisory Board Charter applies to:

- All advisory activities related to the Chimera neural interface system
- All phases of the product lifecycle from concept to post-market
- All geographical markets, with specific focus on US and Indian requirements
- All use environments, including clinical settings and Indian home environments
- All aspects of product development, including technical, clinical, regulatory, commercial, and ethical considerations

## üåê Regulatory Framework

### 2.1 International Standards

- **ISO 13485:2016**: Medical devices ‚Äî Quality management systems ‚Äî Requirements for regulatory purposes
- **ISO 14971:2019**: Medical devices ‚Äî Application of risk management to medical devices
- **IEC 62304:2015**: Medical device software ‚Äî Software life cycle processes
- **IEC 62366-1:2015**: Medical devices ‚Äî Application of usability engineering to medical devices
- **ISO 27001:2022**: Information security management systems ‚Äî Requirements

### 2.2 US FDA Requirements

- **21 CFR Part 820**: Quality System Regulation
- **21 CFR Part 803**: Medical Device Reporting
- **21 CFR Part 806**: Medical Devices; Reports of Corrections and Removals
- **FDA Guidance**: Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions
- **FDA Guidance**: Applying Human Factors and Usability Engineering to Medical Devices
- **FDA Guidance**: Content of Premarket Submissions for Management of Cybersecurity in Medical Devices
- **FDA Guidance**: Software as a Medical Device (SaMD): Clinical Evaluation

### 2.3 Indian CDSCO Requirements

- **Medical Device Rules, 2017** (as amended)
- **CDSCO Guidelines for Software as Medical Device (SaMD)**
- **Digital Personal Data Protection Act, 2023**
- **Bureau of Indian Standards (BIS) IS 23485**: Medical devices ‚Äî Quality management systems ‚Äî Requirements for regulatory purposes
- **CERT-In Guidelines** for cybersecurity
- **Make in India Initiative** requirements for medical devices

### 2.4 Product Classification

Based on thorough analysis of regulatory frameworks:

| Jurisdiction | Classification | Category | Regulatory Pathway |
|--------------|----------------|----------|-------------------|
| **US FDA** | Class II Medical Device | Powered Exoskeleton (Product Code: PHL) | 510(k) clearance with potential De Novo classification for novel aspects |
| **India CDSCO** | Class C Medical Device | Powered Lower Extremity Exoskeleton | Manufacturing license under Form MD-5 |

## üë• Advisory Board Composition

### 3.1 Board Structure

The Advisory Board shall consist of 9-15 members representing diverse expertise, backgrounds, and geographical regions, with particular emphasis on US and Indian markets. The board structure shall include:

- **Core Board**: 9 permanent members with voting rights
- **Extended Board**: Up to 6 additional ad-hoc members for specific expertise
- **Board Chair**: Appointed by Chimera's CEO to lead the Advisory Board
- **Board Secretary**: Appointed by Chimera to manage administrative functions

### 3.2 Required Expertise

The Advisory Board shall collectively possess expertise in the following areas:

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e7YbVlhwJf4-fez_OzCuJUEBbwQb8lYvGvDLZIVUXxA8t5ZJA_WkVYRXdA6JGQvVkWUhLxGRWQMqQhXZJV3pCNcxHmcx1mcx_9i5_uoI1zGeZzHeZzH-b_YRYRXcR7ncR7ncR7nMXZ-jjrCdZzHeZzHeZzHeYyd36KO8C7O4zzO4zzO4zzGzh9RR_gY53Ee53Ee53EeY-fPqCP8ivM4j_M4j_M4j7HzLuoIf-I8zuM8zuM8zmPs_Bt1hMc4j_M4j_M4j_MYO0-ijvAU53Ee53Ee53EeY-c0wlOcx3mcx3mcx3mMnbMIT3Ee53Ee53Ee5zF2ziM8xXmcx3mcx3mcx9i5iPAU53Ee53Ee53EeY-cywnOcx3mcx3mcx3mMnasIz3Ee53Ee53Ee5zF2riO8xHmcx3mcx3mcx9i5ifAS53Ee53Ee53EeY-c2wkucx3mcx3mcx3mMnbsIL3Ee53Ee53Ee5zF27iO8xnmcx3mcx3mcx9h5iPAa53Ee53Ee53EeY-cxwmucx3mcx3mcx3mMnacIb3Ee53Ee53Ee5zF2niO8xXmcx3mcx3mcx9h5ifAW53Ee53Ee53EeY-c1wlucx3mcx3mcx3mMnbcI73Ee53Ee53Ee5zF23iO8x3mcx3mcx3mcx9j5iPAe53Ee53Ee53EeY-czwnucx3mcx3mcx3mMna8IH3Ee53Ee53Ee5zF2viN8xHmcx3mcx3mcx9j5ifAR53Ee53Ee53EeY-e_CB9xHudxHudxHucxdv4HxvXwKQ?type=png" alt="Advisory Board Expertise" width="700px" />
</div>

| Expertise Area | US Market | Indian Market |
|----------------|-----------|---------------|
| **Neurology/Neuroscience** | Minimum 2 members | Minimum 1 member |
| **Physical Medicine & Rehabilitation** | Minimum 1 member | Minimum 1 member |
| **Biomedical Engineering** | Minimum 1 member | Minimum 1 member |
| **Regulatory Affairs** | FDA expert | CDSCO expert |
| **Clinical Research** | US clinical trials expert | Indian clinical trials expert |
| **Patient Advocacy** | US patient representative | Indian patient representative |
| **Reimbursement/Health Economics** | US healthcare system expert | Indian healthcare system expert |
| **Ethics/Bioethics** | Minimum 1 member with cross-cultural expertise |
| **Cybersecurity/Data Privacy** | US regulations expert | Indian regulations expert |

### 3.3 Member Qualifications

Advisory Board members shall meet the following minimum qualifications:

1. **Professional Experience**: Minimum 10 years of relevant experience in their field of expertise
2. **Academic Credentials**: Advanced degree (MD, PhD, or equivalent) in relevant discipline
3. **Industry Knowledge**: Demonstrated understanding of medical device industry
4. **Regulatory Familiarity**: Knowledge of relevant regulatory frameworks
5. **Independence**: No conflicts of interest that would compromise objectivity
6. **Diversity**: Representation across gender, ethnicity, and geographical regions
7. **Communication Skills**: Ability to communicate effectively in English (additional Indian languages valuable for Indian market experts)

### 3.4 Selection Process

The selection process for Advisory Board members shall follow these steps:

1. **Nomination**: Candidates may be nominated by Chimera leadership, existing board members, or through self-nomination
2. **Screening**: Initial screening by Chimera's Regulatory Affairs team
3. **Interview**: Structured interviews with Chimera leadership
4. **Due Diligence**: Background checks and conflict of interest assessment
5. **Approval**: Final approval by Chimera's CEO and Board of Directors
6. **Invitation**: Formal invitation and contract negotiation
7. **Onboarding**: Comprehensive orientation to Chimera's technology and objectives

## üìÖ Term and Appointment

### 4.1 Term Length

- **Initial Term**: Two (2) years
- **Renewal**: Option for renewal for additional one-year terms
- **Term Limits**: Maximum of three consecutive terms (5 years total)
- **Staggered Terms**: Initial appointments shall be staggered to ensure continuity

### 4.2 Appointment Process

1. **Appointment Letter**: Formal appointment letter signed by Chimera's CEO
2. **Contractual Agreement**: Legally binding agreement outlining terms, compensation, and obligations
3. **Confidentiality Agreement**: Execution of comprehensive confidentiality and non-disclosure agreement
4. **Conflict of Interest Disclosure**: Initial and annual disclosure of potential conflicts
5. **Code of Ethics Acknowledgment**: Signed acknowledgment of Advisory Board Code of Ethics

### 4.3 Resignation and Removal

- **Resignation**: Members may resign with 30 days written notice
- **Removal for Cause**: Members may be removed for cause by majority vote of Chimera's Board of Directors
- **Automatic Termination**: Membership automatically terminates upon:
  - Breach of confidentiality
  - Undisclosed conflict of interest
  - Missing three consecutive meetings without valid reason
  - Conduct detrimental to Chimera's reputation or interests

### 4.4 Vacancies

Vacancies shall be filled within 90 days following the established selection process, with interim appointments possible for critical expertise areas.

## üîÑ Meetings and Operations

### 5.1 Meeting Frequency

- **Regular Meetings**: Quarterly (4 times per year)
- **Special Meetings**: As needed for urgent matters
- **Subcommittee Meetings**: As determined by subcommittee chairs
- **Annual Strategic Review**: Once per year (extended session)

### 5.2 Meeting Format

- **Primary Format**: Virtual meetings via secure video conferencing
- **In-Person Meetings**: Minimum one in-person meeting annually
- **Hybrid Options**: Accommodation for remote participation when necessary
- **Location Rotation**: In-person meetings to alternate between US and India

### 5.3 Meeting Procedures

1. **Agenda**: Distributed at least 14 days in advance
2. **Materials**: Supporting materials provided at least 7 days in advance
3. **Minutes**: Comprehensive minutes distributed within 14 days after meeting
4. **Quorum**: Minimum of 60% of Core Board members
5. **Decision-Making**: Consensus-based approach with formal voting when necessary
6. **Voting**: Simple majority of present Core Board members
7. **Language**: All proceedings conducted in English with translation services available

### 5.4 Subcommittees

The Advisory Board may establish subcommittees for specific focus areas:

1. **Clinical & Scientific Subcommittee**
2. **Regulatory & Compliance Subcommittee**
3. **Patient Experience & Usability Subcommittee**
4. **Market Access & Commercialization Subcommittee**
5. **Ethics & Data Governance Subcommittee**

Each subcommittee shall:
- Be chaired by a Core Board member
- Include 3-5 members with relevant expertise
- Meet at least bi-monthly
- Report findings and recommendations to the full Advisory Board

## üí∞ Compensation and Expenses

### 6.1 Compensation Structure

| Member Category | Annual Retainer | Meeting Fee | Equity Compensation |
|-----------------|----------------|-------------|---------------------|
| **Core Board Members** | $15,000 USD | $1,500 USD per meeting | 0.1% - 0.25% equity (vesting over 3 years) |
| **Extended Board Members** | $7,500 USD | $1,500 USD per meeting | 0.05% - 0.1% equity (vesting over 3 years) |
| **Board Chair** | $25,000 USD | $2,000 USD per meeting | 0.25% - 0.5% equity (vesting over 3 years) |
| **Subcommittee Chair** | +$5,000 USD | +$500 USD per subcommittee meeting | Additional 0.05% equity |

### 6.2 Expense Reimbursement

- **Travel Expenses**: Reimbursement for reasonable travel, accommodation, and meals
- **Business Class**: Business class airfare for flights exceeding 6 hours
- **Accommodation**: 4-5 star hotels for in-person meetings
- **Per Diem**: Standard per diem rates for incidental expenses
- **Documentation**: All expenses must be documented with receipts

### 6.3 Payment Terms

- **Retainer**: Paid quarterly in advance
- **Meeting Fees**: Paid within 30 days of meeting attendance
- **Expenses**: Reimbursed within 30 days of submission
- **Equity**: Granted upon appointment with standard vesting schedule
- **Taxes**: Members responsible for all applicable taxes

### 6.4 Compensation Review

Compensation structure shall be reviewed annually and adjusted based on:
- Market rates for comparable advisory positions
- Company growth and financial position
- Individual member contributions and expertise
- Regulatory changes affecting compensation practices

## üîí Confidentiality and Intellectual Property

### 7.1 Confidentiality Obligations

All Advisory Board members shall:
- Maintain strict confidentiality of all non-public information
- Use confidential information solely for Advisory Board duties
- Return or destroy confidential materials upon request
- Continue confidentiality obligations for 5 years after board service
- Immediately report any inadvertent disclosure of confidential information

### 7.2 Intellectual Property Rights

- **Company Ownership**: All intellectual property developed through Advisory Board activities belongs exclusively to Chimera
- **Pre-Existing IP**: Members retain rights to pre-existing intellectual property
- **Improvements**: Improvements to Chimera technology suggested by Advisory Board members are assigned to Chimera
- **Publication Rights**: Chimera maintains right of review for any publications related to Advisory Board work

### 7.3 Conflict of Interest Management

- **Annual Disclosure**: Members must disclose all potential conflicts annually
- **Ongoing Obligation**: Duty to disclose new conflicts as they arise
- **Recusal**: Members must recuse themselves from discussions with potential conflicts
- **Competing Interests**: Members may not serve on advisory boards of direct competitors
- **Cooling-Off Period**: 12-month restriction on joining competitor after board service

## üìä Reporting and Governance

### 8.1 Reporting Structure

<div align="center">
<img src="https://mermaid.ink/img/pako:eNp1kk9PwzAMxb9KlBOI9QvkMG3qBBJiB8QOvUQmMY3WJlWSMjZV_e
(Content truncated due to size limit. Use line ranges to read in chunks)
